These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 29493296)

  • 1. Regression of prostate tumors after intravenous administration of lactoferrin-bearing polypropylenimine dendriplexes encoding TNF-α, TRAIL, and interleukin-12.
    Altwaijry N; Somani S; Parkinson JA; Tate RJ; Keating P; Warzecha M; Mackenzie GR; Leung HY; Dufès C
    Drug Deliv; 2018 Nov; 25(1):679-689. PubMed ID: 29493296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic efficacy of intravenously administered transferrin-conjugated dendriplexes on prostate carcinomas.
    Al Robaian M; Chiam KY; Blatchford DR; Dufès C
    Nanomedicine (Lond); 2014 Apr; 9(4):421-34. PubMed ID: 24910874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced gene expression in the brain following intravenous administration of lactoferrin-bearing polypropylenimine dendriplex.
    Somani S; Robb G; Pickard BS; Dufès C
    J Control Release; 2015 Nov; 217():235-42. PubMed ID: 26362697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor regression following intravenous administration of lactoferrin- and lactoferricin-bearing dendriplexes.
    Lim LY; Koh PY; Somani S; Al Robaian M; Karim R; Yean YL; Mitchell J; Tate RJ; Edrada-Ebel R; Blatchford DR; Mullin M; Dufès C
    Nanomedicine; 2015 Aug; 11(6):1445-54. PubMed ID: 25933695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lactoferrin- and Dendrimer-Bearing Gold Nanocages for Stimulus-Free DNA Delivery to Prostate Cancer Cells.
    Almowalad J; Laskar P; Somani S; Meewan J; Tate RJ; Dufès C
    Int J Nanomedicine; 2022; 17():1409-1421. PubMed ID: 35369035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor regression after systemic administration of a novel tumor-targeted gene delivery system carrying a therapeutic plasmid DNA.
    Koppu S; Oh YJ; Edrada-Ebel R; Blatchford DR; Tetley L; Tate RJ; Dufès C
    J Control Release; 2010 Apr; 143(2):215-21. PubMed ID: 19944722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced gene expression in tumors after intravenous administration of arginine-, lysine- and leucine-bearing polypropylenimine polyplex.
    Aldawsari H; Edrada-Ebel R; Blatchford DR; Tate RJ; Tetley L; Dufès C
    Biomaterials; 2011 Sep; 32(25):5889-99. PubMed ID: 21596431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor regression following intravenous administration of a tumor-targeted p73 gene delivery system.
    Lemarié F; Croft DR; Tate RJ; Ryan KM; Dufès C
    Biomaterials; 2012 Mar; 33(9):2701-9. PubMed ID: 22200536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preferential liver gene expression with polypropylenimine dendrimers.
    Schatzlein AG; Zinselmeyer BH; Elouzi A; Dufes C; Chim YT; Roberts CJ; Davies MC; Munro A; Gray AI; Uchegbu IF
    J Control Release; 2005 Jan; 101(1-3):247-58. PubMed ID: 15588909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Interleukin-12 enhanced tumor necrosis factor related apoptosis-inducing ligand TRAIL-induced apoptosis in human hepatocellular carcinoma by inhibiting expression of survivin].
    He SQ; Chen Y; Chen XP; Zhang WG; Wang HP; Zhang BX
    Zhonghua Wai Ke Za Zhi; 2003 Jun; 41(6):453-7. PubMed ID: 12895357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transferrin-bearing polypropylenimine dendrimer for targeted gene delivery to the brain.
    Somani S; Blatchford DR; Millington O; Stevenson ML; Dufès C
    J Control Release; 2014 Aug; 188():78-86. PubMed ID: 24933602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanoparticle-Mediated Target Delivery of TRAIL as Gene Therapy for Glioblastoma.
    Wang K; Kievit FM; Jeon M; Silber JR; Ellenbogen RG; Zhang M
    Adv Healthc Mater; 2015 Dec; 4(17):2719-26. PubMed ID: 26498165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
    Ray S; Almasan A
    Cancer Res; 2003 Aug; 63(15):4713-23. PubMed ID: 12907654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenovirus-mediated FLT1-targeted proapoptotic gene therapy of human prostate cancer.
    Kaliberov SA; Kaliberova LN; Stockard CR; Grizzle WE; Buchsbaum DJ
    Mol Ther; 2004 Dec; 10(6):1059-70. PubMed ID: 15564138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells.
    Yang B; Wu X; Mao Y; Bao W; Gao L; Zhou P; Xie R; Zhou L; Zhu J
    Neurosurgery; 2009 Sep; 65(3):610-24; discussion 624. PubMed ID: 19687708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted radiotherapy potentiates the cytotoxicity of a novel anti-human DR5 monoclonal antibody and the adenovirus encoding soluble TRAIL in prostate cancer.
    Arafat W; Zhou T; Naoum GE; Buchsbaum DJ
    J Egypt Natl Canc Inst; 2015 Dec; 27(4):205-15. PubMed ID: 26385392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delivery of tumor-homing TRAIL sensitizer with long-acting TRAIL as a therapy for TRAIL-resistant tumors.
    Oh Y; Swierczewska M; Kim TH; Lim SM; Eom HN; Park JH; Na DH; Kim K; Lee KC; Pomper MG; Lee S
    J Control Release; 2015 Dec; 220(Pt B):671-81. PubMed ID: 26381901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiRNA regulation of TRAIL expression exerts selective cytotoxicity to prostate carcinoma cells.
    Huo W; Jin N; Fan L; Wang W
    Mol Cell Biochem; 2014 Mar; 388(1-2):123-33. PubMed ID: 24292881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic action of lactoferrin in enhancing the safety and effectiveness of docetaxel treatment against prostate cancer.
    Muj C; Mukhopadhyay S; Jana P; Kondapi AK
    Cancer Chemother Pharmacol; 2023 May; 91(5):375-387. PubMed ID: 36977771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lovastatin enhances adenovirus-mediated TRAIL induced apoptosis by depleting cholesterol of lipid rafts and affecting CAR and death receptor expression of prostate cancer cells.
    Liu Y; Chen L; Gong Z; Shen L; Kao C; Hock JM; Sun L; Li X
    Oncotarget; 2015 Feb; 6(5):3055-70. PubMed ID: 25605010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.